Investors & Media

  • Webcast
    Q1 2018 Ionis Pharmaceuticals Earnings Webcast
    05/04/18 11:30 am EDT
  • Webcast
    Annual Meeting of Stockholders Webcast
    05/23/18 5:10 pm EDT

Company Profile

Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over three dozen drugs in development. SPINRAZA® (nusinersen) has been approved in the U.S., Europe, Japan, Canada and Brazil for the treatment of spinal muscular atrophy (SMA). Biogen is responsible for commercializing SPINRAZA. Drugs that have successfully completed Phase 3 studies include inotersen , an antisense drug Ionis is developing to treat patients with TTR amyloidosis, and volanesorsen, an antisense drug discovered by Ionis and co-developed by Ionis and Akcea Therapeutics to treat patients with either familial chylomicronemia syndrome or familial partial lipodystrophy. Akcea, an affiliate of Ionis, is a biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. If approved, volanesorsen will be commercialized through Ionis' affiliate, Akcea. Volanesorsen filings for marketing approval have been submitted in the U.S., EU and Canada. Inotersen is progressing toward regulatory filings for marketing authorization. Ionis' patents provide strong and extensive protection for its drugs and technology.

Recent Press Releases

More >>
Date Title and Summary
Toggle Summary FDA Advisory Committee Votes in Favor of WAYLIVRA for Treatment of Familial Chylomicronemia Syndrome
Advisory Committee members vote 12-8 to support approval CAMBRIDGE, Mass. and CARLSBAD, Calif. , May 10, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , and Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the U.S.
Toggle Summary Ionis Reports First Quarter 2018 Financial Results
Total revenues increased by 25%, driven by SPINRAZA royalties More than $2 billion of cash expected upon closing of Biogen transaction Expanded strategic neurology research collaboration with Biogen and invested in TEGSEDI™ commercialization through Akcea Conference call and webcast today, May 4,
Toggle Summary Akcea Reports Financial Results and Highlights for First Quarter 2018
TTR licensing transaction positions Akcea for two rare disease drug launches in 2018 FDA extended TEGSEDI TM (inotersen) PDUFA date to October 6, 2018 $445 million in pro forma cash to fund the company through key milestones in 2019 Conference Call Webcast Thursday, May 3 , 4:30 p.m.
Toggle Summary New Data from IONIS-HTT Rx Phase 1/2 Study Demonstrates Correlation Between Reduction of Disease-causing Protein and Improvement in Clinical Measures of Huntington's Disease
First drug to demonstrate lowering of mutant huntingtin, the disease-causing protein, in people with Huntington's disease CARLSBAD, Calif. , April 24, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today presented top-line data from the Phase

Upcoming Events

More >>

For more information requests, please visit our Information Request page.

If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Copyright Nasdaq. Minimum 15 minutes delayed.